Showing results (1-10 of 99) with videos related to
Sort By:
Pageof 10
Methodist Debakey Cardiovascular Journal|May 4, 2019
HDL and Reverse Cholesterol Transport BiomarkersKayla A Riggs, Anand RohatgiThe Journal of Clinical Psychiatry|November 19, 2020
An Association Between the Inflammatory Biomarker GlycA and Depressive Symptom SeveritySamara Huckvale, Stephanie Reyes, Alexandra Kulikova, et al.Journal of Clinical Medicine|December 11, 2019
Impaired HDL Metabolism Links GlycA, A Novel Inflammatory Marker, with Incident Cardiovascular EventsKayla A Riggs, Parag H Joshi, Amit Khera, et al.American Journal of Preventive Cardiology|September 5, 2022
GlycA, hsCRP differentially associated with MI, ischemic stroke: In the Dallas Heart Study and Multi-Ethnic Study of Atherosclerosis: GlycA, hsCRP Differentially Associated MI, StrokeKayla A Riggs, Parag H Joshi, Amit Khera, et al.Journal of the American Heart Association|September 19, 2025
Role of Lipids and Lipid Management Therapy Among Patients With Peripheral Artery Disease: A Reappraisal of the Current Evidence and Future DirectionsMcCall Walker, Kayla A Riggs, Anand Rohatgi, et al.Progress in Cardiovascular Diseases|May 14, 2015
High-Density Lipoprotein Function Measurement in Human Studies: Focus on Cholesterol Efflux CapacityAnand RohatgiCurrent Atherosclerosis Reports|June 7, 2015
Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?Preethi Mani, Anand RohatgiCurrent Atherosclerosis Reports|January 22, 2014
The role of advanced lipid testing in the prediction of cardiovascular diseaseAlvin Chandra, Anand RohatgiCurrent Opinion in Lipidology|May 24, 2016
Modulating cholesterol efflux capacity to improve cardiovascular diseaseNicholas Brownell, Anand RohatgiCurrent Atherosclerosis Reports|December 30, 2015
HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic TargetAnish Bhatt, Anand RohatgiPageof 10